Otago researchers' discovery unlocks secrets behind cancer drug resistance

(University of Otago) University of Otago research provides insights into an underlying mechanism that could explain why new cancer therapies to help treat metastatic melanoma do not always work on patients, paving the way for predicting which patients will benefit from certain drugs.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Publication date: 1 October 2018Source: Colloids and Surfaces B: Biointerfaces, Volume 170Author(s): M. Gorgizadeh, N. Azarpira, N. SattarahmadyAbstractNanothechnology-mediated photothermal therapy (PTT) is emerging as one of the inspiring alternative modality of cancer therapy that applies near-infrared radiation. High favorability of this approach is due to its minimum invasiveness, safety of non-targeted area, quick recovery, and capable simultaneous imaging. In this approach, photoabsorbing nanomaterials convert energy of infrared light to vibrational motion and generate heat. In the present study, a nanocomposite comp...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
ConclusionWe report the clinical and genomic landscape of a patient with MPTs who had no identifiable unique somatic or germline mutations to explain her predilection to cancer. The treatment course and overall prognosis for this patient is important for understanding future cases with unrelated, metachronous MPTs, the occurrence of which cannot always be explained by underlying genetic mechanisms.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 30 April 2018Source: Seminars in Cancer BiologyAuthor(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. EbertAbstractImmunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhi...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 November 2017Source: Seminars in Cancer BiologyAuthor(s): K. Vermaelen, A. Waeytens, O. Kholmanskikh, M. Van den Bulcke, E. Van ValckenborghAbstractImmunotherapies, specifically checkpoint inhibitors, are becoming an important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. These major challenges can likely be circumvented by implementing a “personalized ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: 15 September 2018Source: Journal of Molecular Liquids, Volume 266Author(s): Sandhra M. Carvalho, Alexandra A.P. Mansur, Nádia S.V. Capanema, Isadora C. Carvalho, Poliane Chagas, Luiz Carlos A. de Oliveira, Herman S. MansurAbstractMalignant melanoma is the most lethal form of skin cancer in humans which is difficult to treat by conventional surgery and chemotherapeutics. Despite unquestionable progresses in recent years demonstrated by anticancer drug carriers to target tumor local microenvironment, it is growing at a rate of one million new cases being reported annually because overcoming the skin ...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Publication date: 1 October 2018Source: Colloids and Surfaces B: Biointerfaces, Volume 170Author(s): M. Gorgizadeh, N. Azarpira, N. SattarahmadyAbstractNanothechnology-mediated photothermal therapy (PTT) is emerging as one of the inspiring alternative modality of cancer therapy that applies near-infrared radiation. High favorability of this approach is due to its minimum invasiveness, safety of non-targeted area, quick recovery, and capable simultaneous imaging. In this approach, photoabsorbing nanomaterials convert energy of infrared light to vibrational motion and generate heat. In the present study, a nanocomposite comp...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
ConclusionWe report the clinical and genomic landscape of a patient with MPTs who had no identifiable unique somatic or germline mutations to explain her predilection to cancer. The treatment course and overall prognosis for this patient is important for understanding future cases with unrelated, metachronous MPTs, the occurrence of which cannot always be explained by underlying genetic mechanisms.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 21 November 2017Source: Seminars in Cancer BiologyAuthor(s): K. Vermaelen, A. Waeytens, O. Kholmanskikh, M. Van den Bulcke, E. Van ValckenborghAbstractImmunotherapies, specifically checkpoint inhibitors, are becoming an important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. These major challenges can likely be circumvented by implementing a “personalized ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 April 2018Source: Seminars in Cancer BiologyAuthor(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. EbertAbstractImmunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhi...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of upstream signaling. Here, we demonstrate that the deubiquitinating enzyme USP28 functions through a feedback loop to destabilize RAF family members. Loss of USP28 stabilizes BRAF enhancing downstream MAPK activation and promotes resistance to RAF inhibitor therapy in culture and in vivo models. Importantly, we demonstrate that U...
Source: The Journal of Experimental Medicine - Category: Internal Medicine Authors: Tags: Solid Tumors Articles Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | International Medicine & Public Health | Melanoma | Skin Cancer